Last reviewed · How we verify

efavirenz; didanosine EC; lamivudine

Bristol-Myers Squibb · Phase 1 active Small molecule

efavirenz; didanosine EC; lamivudine is a Small molecule drug developed by Bristol-Myers Squibb. It is currently in Phase 1 development.

At a glance

Generic nameefavirenz; didanosine EC; lamivudine
SponsorBristol-Myers Squibb
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about efavirenz; didanosine EC; lamivudine

What is efavirenz; didanosine EC; lamivudine?

efavirenz; didanosine EC; lamivudine is a Small molecule drug developed by Bristol-Myers Squibb.

Who makes efavirenz; didanosine EC; lamivudine?

efavirenz; didanosine EC; lamivudine is developed by Bristol-Myers Squibb (see full Bristol-Myers Squibb pipeline at /company/bristol-myers-squibb).

What development phase is efavirenz; didanosine EC; lamivudine in?

efavirenz; didanosine EC; lamivudine is in Phase 1.

Related